Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

Making Medicine Cost More Won’t Make America Healthy Again

by April 14, 2025
April 14, 2025
Making Medicine Cost More Won’t Make America Healthy Again

Jeffrey A. Singer

Last week, President Donald Trump told a National Republican Congressional Committee audience that he intends to impose tariffs on pharmaceutical products entering the United States soon. Finished pharmaceutical products and active pharmaceutical ingredients (APIs) are not subject to the tariffs imposed last week. He hopes to “re-shore” pharmaceutical manufacturing. American patients, already facing declining health care access and rising health care costs, should brace for even greater challenges.

Approximately one-third of finished pharmaceutical products available in the United States are produced domestically. In 2024, the European Union (EU) exported $127 billion in pharmaceuticals to the US, its largest export to this country. Of this amount, $78.61 billion came from Ireland due to its favorable tax and regulatory environment and skilled workforce. In 2023, China exported $2.2 billion in pharmaceutical products to the US.

According to a report from Avalere Health, about 47 percent of APIs used to make medicines that Americans consume are imported from other countries. The EU is the largest foreign source of APIs produced for the US market, accounting for 26 percent, with India in second place at 18 percent. According to the FDA’s Center for Drug Evaluation and Research, API manufacturers operate 13 percent of their facilities in China, 28 percent in the United States, and 59 percent in other countries around the world. One recent study found that 90 percent of generic drugs rely on imported APIs. A 2022 report from the Food and Drug Administration’s Office of Generic Drugs estimated that 91 percent of all prescriptions filled by US pharmacies are filled as generics.

Surveys reveal that people are quite worried about the high prices of prescription drugs. A recent Kaiser Family Foundation (KFF) poll indicated that most Americans believe prescription medicines are too expensive, with 30 percent reporting difficulties in affording them. Trump’s tariffs on finished pharmaceuticals and APIs will raise the cost of most medications.

Pharmaceutical companies can shift the cost of tariffs to American taxpayers by increasing Medicare, Medicaid, and the Veterans Affairs health systems charges. The irony is that taxpayers would offset any revenue gained from the tariffs through these expenditures.

However, in many instances, pharmaceutical companies will find it more difficult to pass the costs to consumers. Drug manufacturers negotiate prices with third-party payers, such as insurers, pharmaceutical benefits managers (PBMs), and certain government programs, often establishing fixed prices or rebates, which limits manufacturers’ ability to increase prices without renegotiating terms. Competition and payer contracts significantly restrict drug prices, so manufacturers may struggle to transfer tariff costs to consumers without jeopardizing contracts or market share.

Manufacturers might raise prices to offset higher costs, but insurers often absorb these increases instead of passing them on to consumers. Tariff-induced cost hikes could lead to higher patient co-pays and out-of-pocket expenses if insurers or PBMs adjust cost-sharing to protect their profit margins. Finally, insurers can pass on their increased costs through higher premiums.

Finally, pharmaceutical companies may have to absorb certain tariff-related costs that they cannot pass on to taxpayers, third-party payers, or consumers. This will lower their profits and leave companies with fewer resources for investing in research and development. Consequently, all of us will bear the cost of diminished pharmaceutical innovation. We will never know which next breakthrough was lost to diminished innovation.

In the end, tariffs on pharmaceuticals won’t just impact balance sheets—they will also affect patients. Whether through higher premiums, increased out-of-pocket costs, or fewer new treatments in the future, American health care consumers will bear the burden. These policies may sound tough on paper, but their real-world effects further strain an already pressured health care system and put lifesaving medications even further out of reach. If the goal is to make medicines more affordable and accessible, punishing the supply chain that delivers them is exactly the wrong approach.

0
FacebookTwitterGoogle +Pinterest
previous post
Trump says Iran must ditch ‘concept of a nuclear weapon’ ahead of more talks
next post
New Poll: Americans Want Congress to Pair Tax Cuts with Spending Cuts

You may also like

Governments Should Not Fund Research

July 31, 2023

Trump Administration Shouldn’t Designate Drug Cartels as Foreign...

February 5, 2025

Ballot Disqualification: The Stakes

February 8, 2024

Are Institutional Investors a Problem in the Housing...

November 13, 2023

List of 120+ Biden Actions to Help Try...

February 23, 2024

More Evidence Debunking Nurse Practitioners’ Critics

October 24, 2023

America’s Violent Extremists: Past Tragedies, Future Threats

April 20, 2023

NAEP Is Worth Exploring, But Educational Freedom Is...

January 29, 2025

The Solution to Every Problem Is Not Another...

January 22, 2024

Friday Feature: Awakening Spirit Homeschool Collaborative

January 26, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Meet ‘China’s man in Lima’ who jetted over to US to collect trains donated by Biden admin

      July 12, 2025
    • Inside Dan Bongino’s tense meeting with White House officials over Jeffrey Epstein fallout

      July 12, 2025
    • Could Butler happen again? Former Secret Service agents weigh in on political violence in 2025

      July 12, 2025
    • DAVID MARCUS: Trump is flunking his MAGA base’s Jeffrey Epstein test

      July 12, 2025
    • A Deep Dive into Duron Ontario Ltd.’s Construction Career

      July 12, 2025
    • One in six UK workers struggling to pay bills as second jobs hit record high

      July 12, 2025

    Categories

    • Business (8,456)
    • Investing (2,118)
    • Politics (16,015)
    • Stocks (3,205)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved